Allergy pill shows promise for MS repair in small trial

NCT ID NCT05359653

Recruiting now Disease control Sponsor: University of California, San Francisco Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jul 02, 2026 · Updated 1 time

Summary

This study tests whether clemastine fumarate, a common allergy medicine, can help repair the protective coating around nerves (myelin) in people with multiple sclerosis. About 74 adults with relapsing-remitting MS will receive either the drug or a placebo, and advanced MRI scans will measure changes in myelin over six months. The goal is to see if this cheap, safe drug can become a first-ever repair therapy for MS.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: clemastine fumarate (an over-the-counter allergy medicine)
What this could lead to: If it works, this could point toward a treatment that repairs damaged nerve insulation in multiple sclerosis, potentially slowing or reversing some disability.
What could go wrong: This is an early-phase trial with only 74 participants, so results may not apply to all MS patients. The drug is being tested for a new use, and it may not show clear benefit on MRI scans.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for MULTIPLE SCLEROSIS BENIGN are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

chronic progressive multiple sclerosis multiple sclerosis primary progressive multiple sclerosis relapsing-remitting multiple sclerosis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

MULTIPLE SCLEROSIS BENIGN MULTIPLE SCLEROSIS BRAIN LESION MULTIPLE SCLEROSIS RELAPSE MULTIPLE SCLEROSIS, CHRONIC PROGRESSIVE MULTIPLE SCLEROSIS, MS MULTIPLE SCLEROSIS, PRIMARY PROGRESSIVE MULTIPLE SCLEROSIS, RELAPSING-REMITTING

Contacts and locations

Locations

Sandler Neurosciences Building, Neurological Clinical Research Unit
RECRUITING

San Francisco, California, 94107, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.